Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.
Paul R BurchardLuis I RuffoloNicholas A UllmanBenjamin S DaleYatee A DaveBailey K HiltyJian YeMary GeorgerRachel JewellChristine MillerLuis De Las CasasWolfgang JarolimekLara PerrymanMatthew M ByrneAnthony LoriaChelsea MarinMariana Chávez VillaJen Jen YehBrian A BeltDavid C LinehanRoberto Hernandez-AlejandroPublished in: Hepatology communications (2024)
CCA upregulates all 5 lysyl oxidase isoforms, and pan-LOX inhibition reverses tumor-induced mechanical forces associated with chemotherapy resistance to improve chemotherapeutic efficacy and reprogram antitumor immune responses. Thus, combination therapy with pan-LOX inhibition represents an innovative therapeutic strategy in CCA.